Skip to main content
Signal8

Zura Bio Ltd (ZURA)

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Zura Bio Limited logo

Zura Bio Limited

NASDAQ:ZURAHealthcare
AH-0.48%$1.03
Close$1.03-4.17%
Mkt Cap$99.7M
EV-
Float68.65M
O/S96.33M
VOL3.52M sh
$ Vol$3.58M
RVOL0.47×
Inst Own71.9%
Net Cash/Sh-
EarningsMar 31 · in 4mo
Dilution
Zura Bio Limited logoNASDAQ:ZURAAH$1.03-0.48%
Upcoming Catalysts
  • Cash runway at this date: 2yr
    Nov 9, 20268d agoPR
Pipeline2 lead-sponsored trials·2 active0 completed

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
  • Phase 2
    Active, not recruiting

    Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

    Tibulizumab

    Systemic Sclerosis (SSc), Scleroderma

    Enrollment
    80
    Start
    Feb 2025
    Primary Completion
    May 2027est.
    Completion
    Jan 2028est.
    NCT06843239
  • Phase 2
    Active, not recruiting

    Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

    Tibulizumab Dose A, Tibulizumab Dose B

    Hidradenitis Suppurativa (HS)

    Enrollment
    247
    Start
    May 2025
    Primary Completion
    Sep 2026
    Completion
    Apr 2027est.
    NCT06993610